Equity Research firms currently have a positive stance on shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $2.38 on a short term basis.
At the time of writing, the stock was trading at $0.86. This represents a change from the opening price of 0.76%. In terms of performance, year to date, the stock is -31.75%. The monthly stock performance comes in at -2.27%. For the quarter, shares are performing at -9.47%. Weekly performance analysis shows the equity at -3.37%.
In taking a look at technical levels, shares are trading -7.43% away from the 50 day simple moving average and -11.76% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -41.60% away from it’s 52- week high and 5.99% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, AVEO Pharmaceuticals, Inc.’s RSI stands at 43.68. In looking at volatility levels, the shares saw weekly volatility of 3.04% and 4.34% over the past month.